We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 4.50 | 0.28% | 1,640.50 | 1,640.00 | 1,640.50 | 1,656.00 | 1,635.00 | 1,642.00 | 5,918,777 | 16:29:57 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.71 | 67.54B |
From Apr 2019 to Apr 2024
LONDON--Pharmaceutical company GlaxoSmithKline PLC (GSK.LN) said Tuesday that the U.S. Food and Drug Administration has approved its Tanzeum, or albiglutide, drug for type 2 diabetes treatment.
MAIN FACTS:
-FDA has approved Tanzeum for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes.
-Tanzeum has been approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
-Approval is based on the results of the company's Phase III Harmony program.
-Anticipates the U.S. launch of Tanzeum in the third quarter of 2014.
-Albiglutide was licensed by the European Medicines Agency in March 2014, under the brand name Eperzan, for use in adult patients with type 2 diabetes.
-Shares on Tuesday closed at 1547 pence, valuing the company at GBP75.17 billion.
-Write to Tapan Panchal at tapan.panchal@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
